[144] Astera Labs, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Astera Labs, Inc. (ALAB) reporting a proposed sale of 150,000 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ. The filing lists an aggregate market value of $27,330,000 for the block and reports total shares outstanding of 166,219,140. The shares were acquired 03/21/2018 in a private acquisition from the issuer and paid in cash. The filing also discloses multiple Rule 10b5-1 sales by related trusts and entities in the past three months totaling 237,100 shares for gross proceeds of $22,136,140.67. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.

Positive

• Planned sale fully disclosed with broker, date, class, and aggregate value
• Acquisition details provided: shares were acquired 03/21/2018 from the issuer and paid in cash
• Recent 10b5-1 sales itemized with dates, amounts, and gross proceeds enhancing transparency

Negative

• Insider/affiliate selling activity is substantial: 237,100 shares sold in the past three months for $22,136,140.67
• Large block planned sale of 150,000 shares (worth $27.33M) could increase near-term share supply

Insights

Financial Analyst

TL;DR: Insider-affiliate selling disclosed: 150,000-share planned sale and substantial 10b5-1 activity—not an earnings event but relevant to share supply.

The Form 144 notifies market participants that an affiliate plans to sell a 150,000-share block valued at $27.33 million on 09/02/2025 via Morgan Stanley Smith Barney. The shares were originally acquired privately from the issuer on 03/21/2018 and paid in cash, indicating these are not recent option exercises or grants. Separately, the schedule of recent 10b5-1 sales shows 237,100 shares sold in the past three months for $22.14 million, which represents quantifiable insider liquidity. For analysts, this filing is a disclosure of insider selling activity and potential near-term share supply; it does not provide operating metrics or forward guidance.

Compliance/Risk Analyst

TL;DR: Filing appears procedurally complete for Rule 144 disclosure and documents recent Rule 10b5-1 sales by affiliated accounts.

The notice identifies the broker, planned sale date, class, and acquisition details required under Rule 144. It also lists multiple 10b5-1 plan sales by named trusts and entities, with exact dates, amounts, and gross proceeds for each trade, supporting transparency about insider dispositions. The seller makes the standard representation regarding absence of undisclosed material adverse information. No indications of omitted required fields are present in the provided content, though signature and specific plan-adoption dates are not shown in the extract provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	150000	27330000.00	166219140	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/21/2018	Private Acquisition from Issuer or an Affiliate	Issuer			150000	03/21/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ALBA 2003 LIVING TRUST U/A DTD 07/29/2003 2345 North First Street San Jose CA 95131	Common	07/21/2025	13259	1471749.00
10b5-1 Sales for CASA ALAMEDA 2007, LLC 2345 North First Street San Jose CA 95131	Common	07/03/2025	1991	181432.07
10b5-1 Sales for ALBA 2003 LIVING TRUST U/A DTD 07/29/2003 2345 North First Street San Jose CA 95131	Common	07/03/2025	29000	2642656.90
10b5-1 Sales for MAR 2011 CHILDRENS TRUST U/A DTD 06/01/2011 2345 North First Street San Jose CA 95131	Common	07/03/2025	29722	2708449.94
10b5-1 Sales for CASA ALAMEDA 2007, LLC 2345 North First Street San Jose CA 95131	Common	07/02/2025	12000	1079386.80
10b5-1 Sales for ALBA 2003 LIVING TRUST U/A DTD 07/29/2003 2345 North First Street San Jose CA 95131	Common	07/02/2025	51000	4587393.90
10b5-1 Sales for MAR 2011 CHILDRENS TRUST U/A DTD 06/01/2011 2345 North First Street San Jose CA 95131	Common	07/02/2025	58000	5217036.20
10b5-1 Sales for CASA ALAMEDA 2007, LLC 2345 North First Street San Jose CA 95131	Common	06/20/2025	3709	374002.21
10b5-1 Sales for ALBA 2003 LIVING TRUST U/A DTD 07/29/2003 2345 North First Street San Jose CA 95131	Common	06/20/2025	16441	1657851.25
10b5-1 Sales for MAR 2011 CHILDRENS TRUST U/A DTD 06/01/2011 2345 North First Street San Jose CA 95131	Common	06/20/2025	21978	2216182.40

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities is ALAB selling under this Form 144?

The filing notifies a proposed sale of 150,000 common shares of Astera Labs, Inc.

When and where is the planned sale scheduled?

The sale is scheduled for 09/02/2025 through Morgan Stanley Smith Barney on NASDAQ.

What is the aggregate market value and shares outstanding reported?

Aggregate market value for the 150,000-share block is reported as $27,330,000; shares outstanding are 166,219,140.

When were the shares acquired and how were they paid for?

The shares were acquired on 03/21/2018 in a private acquisition from the issuer and paid in cash.

Have there been recent insider sales disclosed?

Yes; the filing lists 10b5-1 sales totaling 237,100 shares in the past three months, generating $22,136,140.67 in gross proceeds.

Does the filing include the seller's attestation about material information?

Yes; the seller represents that they do not know of any undisclosed material adverse information regarding the issuer.